1. Home
  2. MBX vs MTLS Comparison

MBX vs MTLS Comparison

Compare MBX & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBX
  • MTLS
  • Stock Information
  • Founded
  • MBX 2018
  • MTLS 1990
  • Country
  • MBX United States
  • MTLS Belgium
  • Employees
  • MBX N/A
  • MTLS N/A
  • Industry
  • MBX
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • MBX
  • MTLS Technology
  • Exchange
  • MBX NYSE
  • MTLS Nasdaq
  • Market Cap
  • MBX 381.4M
  • MTLS 349.7M
  • IPO Year
  • MBX 2024
  • MTLS 2014
  • Fundamental
  • Price
  • MBX $13.75
  • MTLS $5.02
  • Analyst Decision
  • MBX Strong Buy
  • MTLS
  • Analyst Count
  • MBX 6
  • MTLS 0
  • Target Price
  • MBX $37.50
  • MTLS N/A
  • AVG Volume (30 Days)
  • MBX 498.6K
  • MTLS 118.4K
  • Earning Date
  • MBX 08-16-2025
  • MTLS 07-24-2025
  • Dividend Yield
  • MBX N/A
  • MTLS N/A
  • EPS Growth
  • MBX N/A
  • MTLS N/A
  • EPS
  • MBX N/A
  • MTLS 0.11
  • Revenue
  • MBX N/A
  • MTLS $311,850,851.00
  • Revenue This Year
  • MBX N/A
  • MTLS $5.28
  • Revenue Next Year
  • MBX N/A
  • MTLS $7.82
  • P/E Ratio
  • MBX N/A
  • MTLS $47.46
  • Revenue Growth
  • MBX N/A
  • MTLS 2.98
  • 52 Week Low
  • MBX $4.81
  • MTLS $3.93
  • 52 Week High
  • MBX $27.50
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • MBX N/A
  • MTLS 34.00
  • Support Level
  • MBX N/A
  • MTLS $5.14
  • Resistance Level
  • MBX N/A
  • MTLS $5.57
  • Average True Range (ATR)
  • MBX 0.00
  • MTLS 0.24
  • MACD
  • MBX 0.00
  • MTLS -0.10
  • Stochastic Oscillator
  • MBX 0.00
  • MTLS 7.87

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: